BioRestorative Files S-1 for 508K Share Resale; No Proceeds to Company

TL;DR

**BRTX's S-1 is a red flag; existing holders are cashing out 508,592 shares, signaling potential downside pressure without new capital for the company.**

AI Summary

BioRestorative Therapies, Inc. (BRTX) filed an S-1 to register 508,592 shares of common stock for resale by existing selling securityholders. The company will not receive any proceeds from these sales, but will incur legal and accounting expenses related to the registration. BRTX is a clinical-stage biotechnology company focused on cell and tissue protocols, primarily adult stem cells, with two core programs: brtxDisc for disc/spine disease and ThermoStem for metabolic disorders. The company also operates a commercial biocosmeceutical platform, manufacturing a cell-based secretome to reduce fine lines and wrinkles. BRTX's common stock trades on the NASDAQ Capital Market, closing at $1.24 per share on November 17, 2025. Key risks include the need for additional financing, regulatory hurdles for clinical trials, and the ability to commercialize products. The company has commenced a Phase 2 clinical trial for BRTX-100 to treat chronic lower back pain and obtained FDA IND clearance for cervical discogenic pain.

Why It Matters

This S-1 filing signals that existing investors are preparing to liquidate a significant block of 508,592 shares, representing approximately 5.7% of the 8,876,242 shares outstanding, which could exert downward pressure on BRTX's stock price on the NASDAQ Capital Market. For investors, this means potential dilution and increased supply without new capital flowing into the company's operations. Employees and customers should note that the company is not raising new funds through this offering, which could impact future R&D and commercialization efforts in its competitive regenerative medicine and biocosmeceutical markets, where rivals like Mesoblast and Osiris Therapeutics are also vying for market share.

Risk Assessment

Risk Level: high — The risk level is high because BioRestorative Therapies will receive no proceeds from the sale of 508,592 shares by selling securityholders, yet will incur registration expenses. This offering represents a significant portion of the 8,876,242 common shares outstanding, indicating potential dilution and selling pressure without a corresponding capital infusion for the company's operations or clinical trials, such as the ongoing Phase 2 for BRTX-100.

Analyst Insight

Investors should exercise extreme caution and consider this S-1 a bearish signal, as it indicates existing holders are looking to exit. Do not expect a capital infusion for BRTX's operations from this offering; instead, anticipate potential downward pressure on the stock price due to increased supply.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

Negative

total Assets

$10,000,000

total Debt

$0

net Income

Negative

eps

Negative

gross Margin

N/A

cash Position

$1,100,000

revenue Growth

N/A

Key Numbers

• 508,592 — Shares offered by selling securityholders (Represents potential dilution without new capital for the company.)
• $1.24 — Closing stock price (BRTX's closing price on NASDAQ Capital Market on November 17, 2025.)
• 8,876,242 — Common Stock Outstanding (Total shares of common stock currently issued by the company.)
• $0.0001 — Par value per share (Nominal value of each common stock share.)

Key Players & Entities

• BioRestorative Therapies, Inc. (company) — Registrant and issuer of common stock
• Lance Alstodt (person) — President and Chief Executive Officer of BioRestorative Therapies, Inc.
• Fred Skolnik, Esq. (person) — Legal counsel from Certilman Balin Adler & Hyman, LLP
• Certilman Balin Adler & Hyman, LLP (company) — Legal counsel for BioRestorative Therapies, Inc.
• Securities and Exchange Commission (regulator) — Regulatory body overseeing the S-1 filing
• NASDAQ Capital Market (company) — Stock exchange where BRTX common stock is traded
• U.S. Food and Drug Administration (regulator) — Regulatory body for BRTX's therapeutic products
• $1.24 (dollar_amount) — Closing sale price of BRTX common stock on November 17, 2025
• 508,592 (dollar_amount) — Number of shares of common stock offered by selling securityholders
• 8,876,242 (dollar_amount) — Total common stock outstanding

FAQ

Risk Factors

• Need for Additional Financing [high — financial]: The company has a history of operating losses and expects to incur significant expenses in the future as it advances its product candidates through clinical trials and seeks regulatory approval. The company will require substantial additional capital to fund its ongoing operations and research and development activities. Failure to secure adequate financing could materially and adversely affect its business, financial condition, and prospects.
• Clinical Trial and Regulatory Hurdles [high — regulatory]: The success of BRTX's product candidates, including brtxDisc and ThermoStem, is dependent on successful completion of clinical trials and obtaining regulatory approvals from agencies like the FDA. Delays in trials, unexpected adverse events, or failure to meet regulatory requirements could significantly impact development timelines and commercialization prospects. The company has commenced a Phase 2 trial for BRTX-100 and obtained FDA IND clearance for cervical discogenic pain, but further stages are critical.
• Commercialization Challenges [medium — operational]: The company faces challenges in commercializing its products, including market acceptance, competition, and the ability to establish effective sales and marketing channels. The biocosmeceutical platform, while operational, needs to demonstrate sustained revenue generation and growth against established players in the beauty industry.
• Limited Operating History and Profitability [high — financial]: As a clinical-stage biotechnology company, BRTX has a limited operating history and has not generated significant revenue from its core therapeutic programs. The company has incurred substantial net losses since its inception and expects to continue to incur losses for the foreseeable future. This lack of profitability raises concerns about its long-term financial sustainability.
• Resale of Shares by Selling Securityholders [medium — legal]: This S-1 filing relates to the resale of 508,592 shares by existing securityholders. While the company receives no proceeds, the registration incurs legal and accounting expenses. The potential for a large number of shares to be sold into the market could create downward pressure on the stock price, especially if market demand is insufficient.

Industry Context

The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory oversight. Companies like BioRestorative Therapies operate in a competitive landscape where innovation is key, but success is often contingent on securing substantial funding and navigating complex clinical trial pathways. The cell and tissue therapy market, in particular, is a rapidly evolving field with potential for significant breakthroughs but also facing challenges in scalability and long-term efficacy validation.

Regulatory Implications

BRTX's core therapeutic programs are subject to stringent FDA regulations. Obtaining IND clearance for cervical discogenic pain is a positive step, but the company must successfully navigate Phase 2 and Phase 3 trials for BRTX-100 and other candidates. Any delays, adverse findings, or failure to meet regulatory standards could severely impede or halt product development and commercialization.

What Investors Should Do

1. Monitor cash burn and future financing needs.
2. Evaluate progress in clinical trials and regulatory milestones.
3. Assess the commercial viability of the biocosmeceutical platform.

Key Dates

• 2025-11-17: Closing stock price recorded — Indicates current market valuation of the company at $1.24 per share.

Glossary

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. It provides detailed information about the company's business, financial condition, and management. (This filing is crucial for understanding the current offering, the company's status, and potential risks associated with its securities.)

Selling Securityholders

Existing owners of a company's securities who are registering their shares for resale to the public. The company itself does not receive proceeds from these sales. (The registration of shares for resale by existing holders, as in this case with 508,592 shares, can impact stock liquidity and potentially create selling pressure.)

Clinical-stage biotechnology company

A company focused on developing new drugs or therapies that are currently undergoing testing in human clinical trials, rather than being commercially available. (Highlights that BRTX's revenue generation is primarily dependent on the success of its research and development pipeline and regulatory approvals.)

IND Clearance

Investigational New Drug (IND) application clearance from the FDA, which allows a company to proceed with clinical trials of a new drug or therapy in humans. (Indicates that BRTX has met initial regulatory requirements to begin testing its product candidates in human subjects, a key step in drug development.)

Biocosmeceutical platform

A business segment that combines biological or scientifically derived ingredients with cosmetic products, often with claims of therapeutic or health benefits. (Represents a current revenue-generating or potential revenue stream for BRTX, distinct from its clinical-stage therapeutic programs.)

Year-Over-Year Comparison

This S-1 filing focuses on the registration of shares for resale by existing securityholders and does not appear to be a comprehensive update on financial performance compared to a prior period. Therefore, a direct comparison of key metrics like revenue growth or margin changes is not feasible based on the provided context. The primary financial implication highlighted is the ongoing need for capital to fund operations and development, a consistent theme for clinical-stage biotechnology firms.

Key Financial Figures

• $0.0001 — 8,592 shares of common stock, par value $0.0001 per share, of BioRestorative Therapies,
• $1.24 — stock on the NASDAQ Capital Market was $1.24 per share. Investing in our common st
• $1,398,628 — ull, we would receive gross proceeds of $1,398,628. We currently intend to use such procee

Filing Documents

• forms-1.htm (S-1) — 329KB
• ex5.htm (EX-5) — 12KB
• ex10-49.htm (EX-10.49) — 14KB
• ex23-1.htm (EX-23.1) — 3KB
• ex107.htm (EX-FILING FEES) — 67KB
• ex10-49_001.jpg (GRAPHIC) — 22KB
• 0001493152-25-024081.txt ( ) — 574KB
• ex107_htm.xml (XML) — 5KB

Risk Factors

Risk Factors 3 Special Cautionary Note Regarding Forward-Looking Statements 3 Prospectus Summary 4

Use of Proceeds

Use of Proceeds 5 Selling Securityholders 5

Description of Securities

Description of Securities 8 Plan of Distribution 14 Legal Matters 16 Experts 16 This prospectus includes references to our federally registered trademarks, BioRestorative Therapies and Dragonfly design , BRTX-100, ThermoStem and BRTX . The Dragonfly logo is also registered with the U.S. Copyright Office. This prospectus also includes references to trademarks, trade names and service marks that are the property of other organizations. Solely for convenience, trademarks and trade names referred to in this prospectus appear without the ®, SM or ™ symbols, and copyrighted content appears without the use of the symbol ©, but the absence of use of these symbols does not reflect upon the validity or enforceability of the intellectual property owned by us or third parties. ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we have filed with the Securities and Exchange Commission (the “SEC”) pursuant to which the selling securityholders named herein may, from time to time, offer and sell or otherwise dispose of the shares of common stock covered by this prospectus. You should rely only on the information contained or incorporated by reference into this prospectus and any related prospectus supplement. We have not, and the selling securityholders have not, authorized anyone to provide you with different information. No one is making offers to sell or seeking offers to buy these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus and any prospectus supplement is accurate only as of the date on the front of this prospectus or the prospectus supplement, as applicable, and that any information incorporated by reference into this prospectus or any prospectus supplement is accurate only as of the date given in the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable p

View Full Filing

View this S-1 filing on SEC EDGAR